These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Carcinoma in a bladder diverticulum: presentation and treatment outcome. Golijanin D; Yossepowitch O; Beck SD; Sogani P; Dalbagni G J Urol; 2003 Nov; 170(5):1761-4. PubMed ID: 14532771 [TBL] [Abstract][Full Text] [Related]
4. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. Brake M; Loertzer H; Horsch R; Keller H J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163 [TBL] [Abstract][Full Text] [Related]
5. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary? Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448 [TBL] [Abstract][Full Text] [Related]
6. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin. Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815 [TBL] [Abstract][Full Text] [Related]
7. Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors. Chou EC; Lin AT; Chen KK; Chang LS Int J Urol; 2006 Jun; 13(6):682-5. PubMed ID: 16834642 [TBL] [Abstract][Full Text] [Related]
8. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729 [TBL] [Abstract][Full Text] [Related]
9. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer. Demkow T; Alter A; Wiechno P Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238 [TBL] [Abstract][Full Text] [Related]
11. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252 [TBL] [Abstract][Full Text] [Related]
12. [BCG and radiotherapy: the compatibility of 2 conservative treatments for cancer of the urinary bladder]. Sánchez-Martín FM; Palou Redorta J; Regalado Pareja R; Rubio Briones J; Villavicencio Mavric H; Vicente Rodríguez J Arch Esp Urol; 1999 Sep; 52(7):749-58. PubMed ID: 10540765 [TBL] [Abstract][Full Text] [Related]
13. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG). Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936 [TBL] [Abstract][Full Text] [Related]
14. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. Palou J; Laguna P; Millán-Rodríguez F; Hall RR; Salvador-Bayarri J; Vicente-Rodríguez J J Urol; 2001 May; 165(5):1488-91. PubMed ID: 11342902 [TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association. Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T; Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609 [TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study. Yang TB; Zeng FH; Sun ZQ Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038 [TBL] [Abstract][Full Text] [Related]
17. Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. Ito M; Habuchi T; Watanabe J; Higashi S; Nishiyama H; Wang L; Tsuchiya N; Kamoto T; Ogawa O Urology; 2004 Jul; 64(1):74-8. PubMed ID: 15245939 [TBL] [Abstract][Full Text] [Related]
18. Evolution and prognosis of bladder papillomatosis managed by endoscopic resection and endovesical BCG therapy : about 24 cases. Sallami S; Gammoudi A; Cherni R; Chelly I; Horchani A Tunis Med; 2013 Oct; 91(10):573-6. PubMed ID: 24281996 [TBL] [Abstract][Full Text] [Related]
19. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer. Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171 [TBL] [Abstract][Full Text] [Related]
20. [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy]. Huguet J; Gaya JM; Sabaté S; Palou J; Villavicencio H Actas Urol Esp; 2010 Jan; 34(1):63-70. PubMed ID: 20223134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]